Tackling Formalin-Fixed, Paraffin-Embedded Tumor Tissue with Next-Generation Sequencing .......................... 23
C.L. Corless and P.T. Spellman
Commentary on Wagle et al., p. 82

REVIEW
Exemestane for Breast Cancer Prevention:
A Critical Shift? ......................... 25
A. DeCensi, B.K. Dunn, M. Puntoni, A. Gennari, and L.G. Ford

RESEARCH BRIEFS
ATM Mutations in Patients with Hereditary Pancreatic Cancer ......................... 41
Précis: Next-generation sequencing identifies inherited ATM mutations in kindreds with hereditary pancreatic ductal adenocarcinoma.

Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation ......................... 47
Précis: Analysis of a donor–recipient pair with follicular lymphoma reveals the time-course of somatic mutations acquired during lymphomagenesis.

VIEWS
In The Spotlight

A Role for ATM in Hereditary Pancreatic Cancer ............ 14
J. L. Bakker and J.P. de Winter
Commentary on Roberts et al., p. 41

Dissecting “PI3Knss”:
The Complexity of Personalized Therapy for Ovarian Cancer .... 16
R.C. Bast Jr and G.B. Mills
Commentary on Honohan et al., p. 56

The 14-3-3σ Tumor Suppressor
Has Multiple Functions in ErbB2-Induced Breast Cancer .......... 19
N.E. Hynes and T. Smirnova
Commentary on Ling et al., p. 68
Genomic Complexity and AKT Dependence in Serous Ovarian Cancer .......... 56
Précis: Individualized analyses of the PI3K/AKT and RAS pathways will identify ovarian cancers that may respond to AKT inhibition.

Loss of the 14-3-3q Tumor Suppressor Is a Critical Event in ErbB2-Mediated Tumor Progression .......... 68
C. Ling, V-M-T. Su, D. Zuo, and W.J. Muller
Précis: 14-3-3q inactivation accelerates formation and promotes metastasis of ErbB2/HER2-induced tumors.

High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing ....................... 82
Précis: Targeted, sequencing-based profiling of archival tumor samples identifies genetic alterations that can direct personalized therapy.
2 (1)

Cancer Discovery 2012;2:vi-93.

Updated version
Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/2/1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.